LENZ Therapeutics, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsLENZ Therapeutics is a commercial-stage pharmaceutical company focused solely on the launch and global expansion of VIZZ, its FDA-approved aceclidine eye drop for presbyopia.
What they do
LENZ develops and commercializes VIZZ (aceclidine ophthalmic solution) 1.44%, the first FDA-approved aceclidine-based eye drop for presbyopia, launched in the U.S. in August 2025. The company sells directly to eye care professionals and through an ePharmacy partner, with retail pharmacy availability since November 2025. It is also establishing international licensing and distribution partnerships to commercialize VIZZ globally.
Revenue drivers
- VIZZ product sales (U.S.) — Core revenue from monthly pack sales of VIZZ in the U.S., primarily through ePharmacy and retail channels. Q2 2026 product revenue was over $1.7 million on roughly 27,000 packs sold, a 9% increase over Q1 2026.
- Global license agreements — Upfront payments from exclusive commercialization partnerships for ex-U.S. territories, including a fourth-quarter 2025 agreement and a June 2026 agreement with Arrotex for Australia and New Zealand. These partnerships include milestone payments and royalties on future net sales.
- Regulatory and sales milestones — Potential milestone payments tied to regulatory submissions and approvals, such as up to $65 million from Laboratoires Théa for Canada and up to $85 million from Everest Medicines for Greater China. The first milestone related to the Greater China sublicense was received in 2026.
Recent performance
For Q2 2026 (quarter ended June 30, 2026), total revenue was $5.5 million, up from $1.9 million in Q1 2026, including over $1.7 million in product sales. Full-year 2025 revenue was $19.1 million, and the company reported a 2025 net loss of $82.1 million. As of June 30, 2026, cash and marketable securities were $220.0 million, with an accumulated deficit of $300.5 million.
Strategy
Management plans to drive adoption through direct-to-ECP sales, professional sampling, and broad retail availability, supported by a national TV campaign featuring Sarah Jessica Parker. In July 2026, LENZ added a telehealth channel to make prescribing and home delivery more convenient. Internationally, the company is filing marketing applications (UK MAA, EU validation, Canadian NDS) and signing licensing deals to expand global reach. The focus is on converting consumer awareness into adoption and building sustained growth through patient persistence, with early refill data projecting five packs per patient annually.
Risks
- Single-product dependence — The business relies entirely on VIZZ, and there are no other product candidates in development, so any failure to commercialize VIZZ would materially harm the company.
- Market acceptance and competition — VIZZ may not gain sufficient acceptance from ECPs or patients, and it faces competition from existing presbyopia treatments (Vuity, Qlosi, generic Vuity) and a potential new entrant, Yuvezzi, expected to launch in Q2 2026.
- Limited commercial track record — The company has a short operating history in commercialization, incurred net losses every year since inception, and expects continued losses and negative cash flow in early commercialization.
- Regulatory and reimbursement hurdles — VIZZ's success depends on coverage, pricing, and reimbursement decisions, and any delay in international regulatory approvals (UK, EU, Canada) could slow global expansion.
Outlook
Management says Q2 2026 product revenue grew 9% quarter-over-quarter, telehealth should accelerate prescriptions, and early refill trends support sustained demand. They plan to continue expanding global partnerships, with an MAA submitted to the UK MHRA in April 2026 and a Canadian submission in June 2026. The company expects to keep investing in commercialization and may need additional financing to reach positive cash flow.